Trial Profile
A multicentre, open label, randomised phase II study with docetaxel (Taxotere), cisplatin and 5-fluorouracil as induction chemotherapy, combined with hyperfractionated radiotherapy and cetuximab (Erbitux) in locally advanced unresectable squamous cell carcinoma of the head and neck.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 May 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ACCROBAT-II
- 31 May 2021 Status changed from recruiting to completed.
- 14 Jun 2011 New trial record